Market Overview

Analysis: Positioning to Benefit within Oritani Financial, Bio-Rad Laboratories, Compass Diversified, Q2, Medpace, and Engility — Research Highlights Growth, Revenue, and Consolidated Results

Share:

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oritani Financial Corp. (NASDAQ:ORIT), Bio-Rad Laboratories, Inc. (NYSE:BIO), Compass Diversified Holdings (NYSE:CODI), Q2 Holdings, Inc. (NYSE:QTWO), Medpace Holdings, Inc. (NASDAQ:MEDP), and Engility Holdings, Inc. (NYSE:EGL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ORIT DOWNLOAD: http://Fundamental-Markets.com/register/?so=ORIT
BIO DOWNLOAD: http://Fundamental-Markets.com/register/?so=BIO
CODI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CODI
QTWO DOWNLOAD: http://Fundamental-Markets.com/register/?so=QTWO
MEDP DOWNLOAD: http://Fundamental-Markets.com/register/?so=MEDP
EGL DOWNLOAD: http://Fundamental-Markets.com/register/?so=EGL

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Oritani Financial Corp. (NASDAQ:ORIT), Bio-Rad Laboratories, Inc. (NYSE:BIO), Compass Diversified Holdings (NYSE:CODI), Q2 Holdings, Inc. (NYSE:QTWO), Medpace Holdings, Inc. (NASDAQ:MEDP), and Engility Holdings, Inc. (NYSE:EGL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 22nd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ORITANI FINANCIAL CORP. (ORIT) REPORT OVERVIEW

Oritani Financial's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Oritani Financial reported interest income of $37.92MM vs $34.06MM (up 11.33%) and basic earnings per share $0.27 vs $0.25 (up 8.00%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Oritani Financial reported interest income of $142.46MM vs $134.32MM (up 6.06%) and basic earnings per share $1.14 vs $1.25 (down 8.80%). Oritani Financial is expected to report earnings on January 23rd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.26. The estimated EPS forecast for the next fiscal year is $1.00 and is expected to report on July 26th, 2018.

To read the full Oritani Financial Corp. (ORIT) report, download it here: http://Fundamental-Markets.com/register/?so=ORIT

-----------------------------------------

BIO-RAD LABORATORIES, INC. (BIO) REPORT OVERVIEW

Bio-Rad Laboratories' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Bio-Rad Laboratories reported revenue of $535.00MM vs $508.75MM (up 5.16%) and basic earnings per share $0.92 vs $0.63 (up 46.03%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Bio-Rad Laboratories reported revenue of $2,068.17MM vs $2,019.44MM (up 2.41%) and basic earnings per share $0.96 vs $3.87 (down 75.19%). Bio-Rad Laboratories is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $1.25. The estimated EPS forecast for the next fiscal year is $4.95 and is expected to report on February 22nd, 2018.

To read the full Bio-Rad Laboratories, Inc. (BIO) report, download it here: http://Fundamental-Markets.com/register/?so=BIO

-----------------------------------------

COMPASS DIVERSIFIED HOLDINGS (CODI) REPORT OVERVIEW

Compass Diversified's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Compass Diversified reported revenue of $323.96MM vs $252.29MM (up 28.41%) and basic earnings per share $0.10 vs $0.75 (down 86.67%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Compass Diversified reported revenue of $978.31MM vs $727.98MM (up 34.39%) and basic earnings per share $0.51 vs $2.61 (down 80.46%). Compass Diversified is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $1.73 and is expected to report on March 7th, 2018.

To read the full Compass Diversified Holdings (CODI) report, download it here: http://Fundamental-Markets.com/register/?so=CODI

-----------------------------------------

Q2 HOLDINGS, INC. (QTWO) REPORT OVERVIEW

Q2's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Q2 reported revenue of $50.12MM vs $38.31MM (up 30.83%) and basic earnings per share -$0.14 vs -$0.24. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Q2 reported revenue of $150.22MM vs $108.87MM (up 37.99%) and basic earnings per share -$0.92 vs -$0.67. Q2 is expected to report earnings on February 14th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is -$0.39 and is expected to report on February 14th, 2018.

To read the full Q2 Holdings, Inc. (QTWO) report, download it here: http://Fundamental-Markets.com/register/?so=QTWO

-----------------------------------------

MEDPACE HOLDINGS, INC. (MEDP) REPORT OVERVIEW

Medpace's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Medpace reported revenue of $110.64MM vs $107.80MM (up 2.64%) and basic earnings per share $0.25 vs $0.14 (up 78.57%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Medpace reported revenue of $421.58MM vs $359.06MM (up 17.41%) and basic earnings per share $0.38 vs -$0.28. Medpace is expected to report earnings on February 26th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $1.78 and is expected to report on February 26th, 2018.

To read the full Medpace Holdings, Inc. (MEDP) report, download it here: http://Fundamental-Markets.com/register/?so=MEDP

-----------------------------------------

ENGILITY HOLDINGS, INC. (EGL) REPORT OVERVIEW

Engility's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Engility reported revenue of $487.14MM vs $511.80MM (down 4.82%) and basic earnings per share $0.27 vs -$0.46. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Engility reported revenue of $2,076.42MM vs $2,085.62MM (down 0.44%) and basic earnings per share -$0.29 vs -$7.02. Engility is expected to report earnings on March 1st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.51. The estimated EPS forecast for the next fiscal year is $2.21 and is expected to report on March 1st, 2018.

To read the full Engility Holdings, Inc. (EGL) report, download it here: http://Fundamental-Markets.com/register/?so=EGL

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!